Recent 8-K filings for BLGO
Highest-materiality recent filing
BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable
- Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.
- BioLargo expects substantial impairment of its $3.486M note receivable from Pooph on its June 30 balance sheet.
-
BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners
Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.
-
BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M
Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.
-
Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.
-
BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag
Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.
-
BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%
Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.
-
BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows
Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.
-
BioLargo reports record Q1 revenue, positive operating cash flow of $481K
Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.38 · Most common event other_material